Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CORBF
Global Cord Blood
$0.71
+29.1%
$1.00
$0.25
$2.00
$86.30M-0.52105,408 shs660 shs
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.33
-14.8%
$0.32
$0.25
$1.19
$17.03M1.19173,401 shs4.12 million shs
Kindly MD, Inc. stock logo
KDLY
Kindly MD
$10.97
+0.6%
$15.62
$0.65
$34.77
$66.06MN/A2.29 million shs101,294 shs
NAKA
KindlyMD
$10.97
+0.6%
$0.00
$0.65
$34.77
$79.63M35.16290,182 shs98,589 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CORBF
Global Cord Blood
+29.09%+29.09%-52.67%-32.38%-52.98%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00%0.00%0.00%0.00%-72.22%
Kindly MD, Inc. stock logo
KDLY
Kindly MD
-5.71%-4.64%-28.80%+502.21%+238.51%
NAKA
KindlyMD
+0.64%-0.45%-22.31%+1,096,999,900.00%+1,096,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CORBF
Global Cord Blood
N/AN/AN/AN/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/AN/AN/AN/AN/AN/AN/AN/A
Kindly MD, Inc. stock logo
KDLY
Kindly MD
N/AN/AN/AN/AN/AN/AN/AN/A
NAKA
KindlyMD
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CORBF
Global Cord Blood
0.00
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
0.00
N/AN/AN/A
Kindly MD, Inc. stock logo
KDLY
Kindly MD
0.00
N/AN/AN/A
NAKA
KindlyMD
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CORBF
Global Cord Blood
$196.12M0.44$0.51 per share1.40N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$29.09M0.59N/AN/A$1.09 per share0.30
Kindly MD, Inc. stock logo
KDLY
Kindly MD
$2.47M26.74N/AN/AN/A
NAKA
KindlyMD
$2.72M29.48N/AN/A$0.43 per share25.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CORBF
Global Cord Blood
$79.04MN/A0.00N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
-$26.08MN/A0.00N/A-75.34%-7.96%-5.49%N/A
Kindly MD, Inc. stock logo
KDLY
Kindly MD
N/A-$0.77N/AN/AN/AN/AN/AN/A
NAKA
KindlyMD
-$3.62M-$0.77N/AN/A-177.01%-146.26%-109.19%N/A

Latest ENZ, CORBF, NAKA, and KDLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Kindly MD, Inc. stock logo
KDLY
Kindly MD
N/A-$0.17N/A-$0.17N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CORBF
Global Cord Blood
N/AN/AN/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
$0.40123.08%N/AN/AN/A
Kindly MD, Inc. stock logo
KDLY
Kindly MD
N/AN/AN/AN/AN/A
NAKA
KindlyMD
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CORBF
Global Cord Blood
N/AN/AN/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
N/A
2.55
2.28
Kindly MD, Inc. stock logo
KDLY
Kindly MD
N/A
5.43
5.42
NAKA
KindlyMD
N/A
2.30
2.30

Institutional Ownership

CompanyInstitutional Ownership
CORBF
Global Cord Blood
N/A
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
36.90%
Kindly MD, Inc. stock logo
KDLY
Kindly MD
N/A
NAKA
KindlyMD
N/A

Insider Ownership

CompanyInsider Ownership
CORBF
Global Cord Blood
0.50%
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
11.40%
Kindly MD, Inc. stock logo
KDLY
Kindly MD
50.50%
NAKA
KindlyMD
50.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
CORBF
Global Cord Blood
1,200121.55 millionN/ANot Optionable
Enzo Biochem, Inc. stock logo
ENZ
Enzo Biochem
52052.40 million46.29 millionOptionable
Kindly MD, Inc. stock logo
KDLY
Kindly MD
N/A6.02 million2.96 millionN/A
NAKA
KindlyMD
N/A7.31 million3.62 millionN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Global Cord Blood NYSE:CORBF

$0.71 +0.16 (+29.09%)
As of 07/25/2025 03:49 PM Eastern

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

Enzo Biochem stock logo

Enzo Biochem NYSE:ENZ

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Kindly MD stock logo

Kindly MD NASDAQ:KDLY

$10.97 +0.07 (+0.64%)
As of 07/25/2025

Kindly MD, Inc. provides healthcare services. Its services include medication management, behavioral healthcare and alternative treatments. The firm offers evaluation and management, including chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy. The company was founded by Timothy Pickett in December 2019 and is headquartered in Murray, UT.

KindlyMD NASDAQ:NAKA

$10.97 +0.07 (+0.64%)
As of 07/25/2025 04:00 PM Eastern

Kindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.